Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Scott Biller sold 2,146 shares of the business’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $55.00, for a total value of $118,030.00. Following the completion of the sale, the insider now owns 8,410 shares of the company’s stock, valued at $462,550. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Scott Biller also recently made the following trade(s):

  • On Wednesday, June 21st, Scott Biller sold 4,292 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $55.00, for a total value of $236,060.00.

Shares of Agios Pharmaceuticals, Inc. (AGIO) traded up 3.36% during trading on Tuesday, reaching $56.33. The company’s stock had a trading volume of 515,226 shares. The stock’s 50-day moving average is $51.10 and its 200-day moving average is $49.19. Agios Pharmaceuticals, Inc. has a 12-month low of $35.84 and a 12-month high of $67.74. The stock’s market cap is $2.72 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.24. The firm had revenue of $10.51 million for the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The company’s quarterly revenue was down 66.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.64) earnings per share. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post ($6.44) earnings per share for the current fiscal year.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/insider-selling-agios-pharmaceuticals-inc-agio-insider-sells-2146-shares-of-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S purchased a new position in Agios Pharmaceuticals during the first quarter worth $105,000. Bank of Montreal Can boosted its stake in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth approximately $129,000. Russell Investments Group Ltd. boosted its stake in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC boosted its stake in shares of Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares in the last quarter. Institutional investors own 83.66% of the company’s stock.

Several analysts recently issued reports on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, June 11th. Cann restated a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 18th. Zacks Investment Research upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 28th. Finally, ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $62.88.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.